Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR REGISTRATION OF THE PUBLIC ISSUANCE OF CORPORATE BONDS

References are made to the announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") dated 24 June 2025 and the circular of the Company dated 20 May 2025 (the "**Circular**") in relation to, among other things, the proposed public issuance of corporate bonds (the "**Corporate Bonds**") in the PRC. Unless otherwise specified, capitalised terms used herein shall have the same meanings as defined in the Circular.

Recently, the Company has received the Approval on the Public Issuance of the Science and Technology Innovation Corporate Bonds to the Professional Investors by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Zheng Jian Xu Ke [2026] No.298) (the "**Approval**") issued by China Securities Regulatory Commission (the "**CSRC**").

Pursuant to the Approval, the CSRC has approved application for registration of the Company to publicly issue the Science and Technology Innovation Corporate Bonds not exceeding RMB6 billion to professional investors. The Approval shall be valid within 24 months from the date of approval for registration. The Company may issue the Science and Technology Innovation Corporate Bonds in tranches within the validity period of registration.

The Company will proceed with the issuance of the Science and Technology Innovation Corporate Bonds in accordance with relevant laws and regulations, the Approval and the authorization from the general meeting of the Company. The issuance will be conducted at the appropriate time within the validity period of registration, taking into account the Company's funding needs and market conditions, and the Company will fulfil the disclosure obligations in a timely manner.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
26 February 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee Director of the Company is Ms. Yan Jia.

* *For identification purposes only*